BUSINESS LIVE BofE base rate decision; AstraZeneca flags China fine; Babcock lifts guidance

The boss of pharma giant GSK has said the Government must ‘step up’ to stop Britain’s drugs industry being overtaken by foreign rivals.

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing business in the UK.

Mark Crouch, market analyst at eToro:

‘Compass Group is coming off a stellar year, with earnings growth soaring for the British catering giant.

‘Despite facing inflationary pressures and rising costs, Compass Group’s efficiency in implementing cost-saving initiatives has allowed the business to protect its profit margins, drive up earnings and, in turn, boost its share price, which has more than trebled since the pandemic.

‘Compass Group’s rapid growth in Europe, and particularly in North America, has been driven by a notable uptick in employees returning to the office. As high street food prices hit record levels, many employees have opted to dine at the company’s on-site canteens, fueling demand for its services.’

Catering group Compass has reported first-quarter organic revenue growth of 9.2 per cent, supported by strength across its markets, especially North America.

The world’s largest food catering firm, which serves offices, hospitals and universities in about 30 markets, retained its annual outlook and said all regions and sectors performed well in the final three months of 2024.

The London-listed firm has been benefiting from the trend of global firms requiring employees to return to office, boosting office canteen spending, as cost-conscious employees preferred eating in canteens over pricier high-street restaurants.

‘We are an even more focused business and are leveraging investments in capex and M&A to support future growth,’ Compass said.

Sheena Berry, healthcare analyst at Quilter Cheviot:

‘China has proven to be an overhang on the stock following the fraud investigations of several individuals, and questions remain on exactly what impact this might have on operations in China.

‘Sales declined 3% in the region, largely as a result of lower rates of seasonal respiratory viral infections and tightening hospital budgets. While the import tax allegation is certainly a headline generating blemish on the company, it appears manageable.

‘Looking ahead, 2025 guidance implies another year of solid growth is anticipated by management. AstraZeneca is guiding to high single digit total revenue growth in 2025, with earnings per share expected to increase to low double digits.

‘2025 is expected to be a catalyst rich year, and this should help provide investors with confidence in the group’s $80bn revenue ambition in 2030.’

Defence group Babcock has hiked revenue expectations for the year on the back of strength in its nuclear and marine segments.

The group expects to post around £4.9billion pounds in sales for the year, compared to analyst forecasts of approximately £4.67billion.

Boss David Lockwood said: ‘Today’s announcement demonstrates that successful execution of our strategy is continuing to deliver value for all our stakeholders.

‘Our engineering skills and know-how are in ever greater demand and with significant opportunities before us, I look forward to further profitable growth.’

AstraZeneca faces a potential fine over unpaid taxes in China, the drugmaker told investors this morning.

The FTSE 100 firm has received a notice in China over unpaid taxes related to the import of two cancer therapies.

It comes at AstraZeneca continues to gauge the impact of probes into certain executives and activities in the key market.

Last December, AstraZeneca named Iskra Reic as its new international executive vice president, who took over from Leon Wang in its efforts to stabilise its operations in China, after Wang was detained by Chinese authorities in October.

A fine of between one and five times the unpaid tax amount of $0.9million may be levied if the company is found liable.

It came as the group reported fourth-quarter earnings and forecast 2025 sales above analyst expectations.

The Bank of England’s Monetary Policy Committee will reveal its decision on the direction of interest rates later today.

Markets are firmly pricing a 25 basis point base rate cut to 4.5 per cent and investors be looking closely at the bank’s commentary for clues as to the future of monetary policy.

Peder Beck-Friis, economist at Pimco, said:.

‘Looking ahead, we see room for deeper cuts than what financial markets expect. Trade uncertainty is rising, labour demand is falling, fiscal policy is tight, and the policy rate is well above our neutral estimate of 2 to 3 per cent.

‘While inflation will likely rise in the coming quarters, the main driver—the national insurance hike—is a one-time tax shock that central banks typically look through. If wage growth falls and the labour market weakens, we expect the Monetary Policy Committee to look through any short-term price pressures and instead focus on the medium-term outlook.

‘Recent weeks have seen a significant decline in gilt yields. We think gilts remain attractive at their current levels.’